Protective immunity against novel coronavirus may last for over eight months: Study
PTI, Jan 7, 2021, 2:16 PM IST
New Delhi: COVID-19 survivors may have protective immunity against serious disease from the SARS-CoV-2 virus for months, or even years after the infection, a study suggests.
The findings, based on analyses of blood samples from 188 COVID-19 patients, suggest that nearly all survivors of the disease have the immune cells necessary to fight re-infection.
“Our data suggest that the immune response is there — and it stays,” Professor Alessandro Sette from La Jolla Institute for Immunology in the US.
The researchers measured antibodies, memory B cells, helper T cells and killer T cells — all four components of immune memory — at the same time.
The study, published in the journal Science, helps clarify some concerning data from other institutes, which showed a dramatic drop-off of COVID-fighting antibodies in the months following infection.
Some feared that this decline in antibodies meant that the body wouldn’t be equipped to defend itself against reinfection.
Sette explained that a decline in antibodies is very normal.
“Of course, the immune response decreases over time to a certain extent, but that’s normal,” he noted.
“That’s what immune responses do. They have a first phase of ramping up, and after that fantastic expansion, eventually the immune response contracts somewhat and gets to a steady-state,” Sette added.
The researchers found that virus-specific antibodies do persist in the bloodstream months after infection.
They said the body also has immune cells called memory B cells at the ready, adding that if a person encounters SARS-CoV-2 again, these cells could reactivate and produce antibodies to fight re-infection.
The SARS-CoV-2 virus uses its “spike” protein to initiate infection of human cells, so the researchers looked for memory B cells specific for the SARS-CoV-2 spike.
They found that spike-specific memory B cells actually increased in the blood six months after infection.
“COVID-19 survivors also had an army of T cells ready to fight reinfection. Memory CD4+ “helper” T cells lingered, ready to trigger an immune response if they saw SARS-CoV-2 again,” the researchers said.
Many memory CB8+ “killer” T cells also remained, ready to destroy infected cells and halt a reinfection, they said.
“The different parts of the adaptive immune systems work together, so seeing COVID-fighting antibodies, memory B cells, memory CD4+ T cells and memory CD8+ T cells in the blood more than eight months following infection is a good sign,” said LJI Professor Shane Crotty.
“This implies that there’s a good chance people would have protective immunity, at least against serious disease, for that period of time, and probably well beyond that,” Crotty said.
However, the researchers cautioned that protective immunity does vary dramatically from person to person.
They saw a 100-fold range in the magnitude of immune memory.
“People with a weak immune memory may be vulnerable to a case of recurrent COVID-19 in the future, or they may be more likely to infect others,” the researchers said.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
World COPD Day: Know your lung function
As Delhi chokes with dangerous pollution levels, doctors warn of health risks for all
World Diabetes Day 2024: Kasturba Hospital Manipal Hosts Zumba Session at Malpe Beach to Raise Diabetes Awareness
World Diabetes Day: An overview of types of diabetes
World Diabetes Day: One-fourth of people living with diabetes in 2022 are in India, Lancet study estimates
MUST WATCH
Latest Additions
Siddaramaiah says confident of winning all three bypolls in Karnataka
Hop on! IT Minister Priyank Kharge checks out Uber Shuttle at Bengaluru Tech Summit
Actress Kasthuri released from jail, says ‘I thank those who made me raging storm’
Kidnapped for ransom in 1998, 26/11 survivor Gautam Adani faces biggest trial
AIMPLB to hold its annual general sessions in Bengaluru from November 23
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.